These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26928381)

  • 1. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
    Rosenberg AS; Klein AK; Ruthazer R; Evens AM
    Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.
    Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
    Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
    Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
    Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
    Twist CJ; Hiniker SM; Gratzinger D; Gutkin PM; Merriott DJ; Iagaru A; Link MP; Donaldson SS
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27803. PubMed ID: 31062898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal involvement by lymphoproliferative disorders post-renal transplantation: a report from the post-transplant lymphoproliferative disorder international survey.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):487-94. PubMed ID: 23640619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of Patients With Second Primary Hodgkin Lymphoma.
    Budnik J; Doucette C; Milano MT; Constine LS
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):316-323.e2. PubMed ID: 32014390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
    Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.
    Zhou K; Gong D; Han Y; Huang W
    Ann Hematol; 2024 Jul; 103(7):2207-2213. PubMed ID: 37749317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
    J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
    Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
    Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
    Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
    J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
    Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
    J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
    Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
    Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.